Navigation Links
VBI, Mayo Clinic investigate link between fungal proteins, innate immunity and asthma
Date:2/27/2008

Blacksburg, Va. Researchers at Mayo Clinic and the Virginia Bioinformatics Institute (VBI) have received a second grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance understanding of the role of environmental fungi in chronic airway disorders. Recently NIAID awarded the researchers a further $1.8 million for these studies over a five-year period to investigate how the environmental fungus Alternaria triggers airway inflammation and bronchial asthma. Exposure to the fungus Alternaria has long been implicated in the development and exacerbation of asthma, especially life-threatening asthma, although little is known about the molecular events in the immune system that underlie the etiology and progress of this chronic disease. By understanding how the innate immune system responds to environmental stimuli and helps shape the adaptive immune system, scientists hope in the long term to develop more specific therapies as well as prevention strategies for bronchial diseases.

Principal Investigator Hirohito Kita, M.D., from Mayo Clinic, remarked: In this investigation, we will be looking closely at how fungal enzymes from Alternaria cause innate immune responses in a variety of cells and how they influence nave T cells in the immune system to differentiate into T helper 2 cells or Th2 cells, a process which takes place in partnership with antigen-presenting cells called dendritic cells. Th2 cells are part of the adaptive immune system and are linked to the events that lead to inflammation of the airway. He added: Th2 cells typically produce cytokine signaling molecules or interleukins and the production of these interleukins leads to the recruitment of a specific class of white blood cells (eosinophils) that usually destroy parasitic organisms larger than bacteria or viruses. Mounting evidence suggests that allergic airway disorders such as asthma and chronic sinusitis are actually the result of our bodies believing we are being attacked by parasites. Environmental fungi such as Alternaria do not typically cause invasive infections like parasites but for some reason, in certain people, the body thinks it is being attacked. This results in Th2 cells constantly recruiting eosinophils and chronic inflammation occurs because humans are continually exposed to common environmental fungi like Alternaria.

The hypothesis that will be tested is that certain immunoactive enzymes from Alternaria activate dendritic cells through yet unidentified receptors that allow for tailoring of the adaptive immune response and the formation of Th2 cells. This in turn leads to the strong immune responses in the airways. The research team will use different approaches to determine the potential role of these receptors in the cascade of immune interactions that comprise inflammation of the airways. This should allow them to better understand how certain environmental stimuli are linked via the innate immune system to the adaptive immune system and development of inflammation and disease.

Dr. Chris Lawrence, Associate Professor at VBI and the Department of Biological Sciences at Virginia Tech, one of the leading experts in Alternaria biology and principal investigator of the Alternaria genome sequencing project funded by the National Science Foundation-United States Department of Agriculture (NSF-USDA) Microbial Genome Sequencing Program, stated: Our part of the collaboration is critical and will involve the use of proteomics and functional genomics approaches to identify the novel enzymes produced by Alternaria that are triggers of innate immune responses that shape the adaptive immune system. Recombinant fungal proteins will be used to dissect the different molecular steps involved in the development and progression of inflammation and asthma. He added: We will create a series of fungal knockout mutants for specific genes that will be used to examine the specific role of fungal proteins in the activation of the innate immune system response. It is our belief that understanding how and why asthma patients develop Th2 immune responses to environmental proteins is one of the prerequisites for the future development of treatments, diagnostic tools and preventative measures for patients suffering from the disease. We are truly excited about being able to participate in this transdisciplinary, team-based scientific effort.

Asthma is a chronic disease characterized by recurrent attacks of breathlessness and wheezing. The most common chronic disease among children, it currently affects 300 million people worldwide.* In 2000, the Asthma and Allergy Foundation of America estimated that direct health care costs for asthma in the United States total more than $10 billion annually; indirect costs (lost productivity) add another $8 billion for a total of $18 billion. In 2005 alone, 255 000 people died of asthma worldwide.*


'/>"/>

Contact: Barry Whyte
whyte@vbi.vt.edu
540-231-1767
Virginia Tech
Source:Eurekalert

Related medicine news :

1. Does artificial intelligence help clinicians to recognize atrophic gastritis with thyroid disease?
2. HealthpointCapital, LLC Appoints Stephen H. Hochschuler, M.D. as Clinical Advisor
3. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
4. Pharsight to Present at eClinical Forum
5. PRA International to Open Expanded Clinical Pharmacology Center
6. Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions
7. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
8. Professional Products, Inc. Integrates Clinical Skills and Simulation Center at the Johns Hopkins Hospital
9. Algeta Receives IND Approval for Alpharadin(TM) to Commence Clinical Development in the USA
10. Cleveland Clinic Collaborates with Google
11. Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... In ... the many who are unaware of the plight of aphasia. In collaboration with ... the “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... to students studying complementary medicine. Allison Outerbridge is this year’s Life University ... on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... New Hampshire (PRWEB) , ... May 26, 2016 , ... ... skin care products, has been honored with a 2016 When Work Works Award for ... prestigious award, part of the national When Work Works project administered by the Families ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 LabStyle ... Dario™ Diabetes Management Tool, today announced that the Company,s Chief ... Marcum MicroCap Conference being held June 1-2 in ... being held June 7-9 in Los Angeles, CA. ... discuss recent corporate and operational milestones, including the U.S. FDA ...
(Date:5/27/2016)... Kitov Pharmaceuticals ... late-stage drug development, today announced the completion of ... batches required for registration of KIT-302 with the ... Kitov,s announcement in December 2015, that ... primary efficacy endpoint. "We are fortunate ...
(Date:5/26/2016)... 2016 According to a new market ... - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast ... U.S. was valued at US$ 5.89 Bn in 2014 and ... 2015 to 2023 to reach US$ 7.99 Bn in 2023. ... emerging needle free drug delivery devices and the market is ...
Breaking Medicine Technology: